日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

CONFIRM:一项安慰剂对照、随机 III 期试验表明,构成性炎症和上皮-间质转化决定了对纳武利尤单抗的敏感性。

Fennell, Dean A; Hill, Kayleigh; Zhang, Min; Poile, Charlotte; Ewings, Sean; Baitei, Essa Y; Dzialo, Joanna; Nusrat, Nada; Rogel, Jan; Faulkner, Daniel; Ottensmeier, Christian; Califano, Raffaele; Hanna, Gerard G; Danson, Sarah; Steele, Nicola; Nye, Mavis; Johnson, Lucy; Mallard, Kim; Lord, Joanne; Middleton, Calley; Szlosarek, Peter; Chan, Sam; Darlison, Liz; Wells-Jordan, Peter; Richards, Cathy; Harber, James; Bzura, Aleksandra; Spicer, Jake; Pritchard, Catrin; Kamata, Tamihiro; Hahne, Jens C; Jama, Maymun; Hollox, Edward J; Lester, Jason F; Luo, Jin-Li; Zhou, Zisen; Yang, Hongji; Zhou, Huiyu; Klampatsa, Astero; Griffiths, Gareth O

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

在 AGILE IIa 期临床试验中,对 SARS-CoV-2 基因组变异对 molnupiravir 治疗的反应进行表征

Donovan-Banfield I'ah, Penrice-Randal Rebekah, Goldswain Hannah, Rzeszutek Aleksandra M, Pilgrim Jack, Bullock Katie, Saunders Geoffrey, Northey Josh, Dong Xiaofeng, Ryan Yan, Reynolds Helen, Tetlow Michelle, Walker Lauren E, FitzGerald Richard, Hale Colin, Lyon Rebecca, Woods Christie, Ahmad Shazaad, Hadjiyiannakis Dennis, Periselneris Jimstan, Knox Emma, Middleton Calley, Lavelle-Langham Lara, Shaw Victoria, Greenhalf William, Edwards Thomas, Lalloo David G, Edwards Christopher J, Darby Alistair C, Carroll Miles W, Griffiths Gareth, Khoo Saye H, Hiscox Julian A, Fletcher Thomas